Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
January 2013, Vol 4, No 1
January 2013, Vol 4, No 1
Ibrutinib: It’s Not Just for Leukemia
By
Audrey Andrews
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—The investigational agent ibrutinib, which is making news in the treatment of patients with leukemia, demonstrated “unprecedented” single-agent activity in patients with relapsed or refractory mantle-cell lymphoma (MCL), according to the lead author of an international phase 2 study that was reported at the 2012 American Society of Hematology meeting.
Read Article
Chemotherapy-Free Regimen Tops Standard for Treating Patients with Acute Promyelocytic Leukemia
By
Charles Bankhead
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—A chemotherapy-free regimen for patients with acute promyelocytic leukemia (APL) achieved a 2-year survival of almost 100% with less toxicity compared with cytotoxic regimens, according to a study reported at the 2012 American Society of Hematology (ASH) meeting.
Read Article
Regenerative Medicine the Focus of Presidential Symposium
By
Mark Knight
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—The promise of regenerative medicine is exemplified by the regeneration of corneal epithelium from human limbal stem-cell culture.
Read Article
Novel Drug Targets Aggressive Form of NHL, Avoiding Chemotherapy a Goal
Value Propositions
,
Value Peer-spectives
January 2013, Vol 4, No 1
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and a common type of cancer.
Read Article
First Group to Test Nanoparticles for the Treatment of Lung Cancer
Value Propositions
,
Value Peer-spectives
January 2013, Vol 4, No 1
Cancer Treatment Centers of America (CTCA) in Philadelphia, PA, is the first US center to investigate the use of nanotherapy for the treatment of metastatic lung cancer.
Read Article
Genomics Can Reduce Healthcare Disparities
Value Propositions
,
Value Peer-spectives
January 2013, Vol 4, No 1
Read Article
First Genomic Biomarker in Development for Multiple Myeloma
Value Propositions
,
Value Peer-spectives
January 2013, Vol 4, No 1
Empire Genomics is developing the first molecular diagnostic test for multiple myeloma (MM) using a novel genomic biomarker from Emory University that will allow providers to select the right treatments for the right patients based on their genetic profile.
Read Article
Cometriq Only Second Drug Approved for Metastatic Medullary Thyroid Cancer
ASCO’s 1st Quality Care Symposium
,
ASCO
January 2013, Vol 4, No 1
Cabozantinib (Cometriq; Exelixis) is the second drug ever to be approved by the FDA for the treatment of patients with metastatic medullary thyroid cancer.
Read Article
Zytiga Receives New Indication for Metastatic Prostate Cancer before Chemotherapy
FDA Approvals, News & Updates
January 2013, Vol 4, No 1
Using its priority review process, the FDA approved a new indication for abiraterone acetate (Zytiga; Janssen Biotech) for the treatment of patients with metastatic, castration-resistant prostate cancer (CRPC) before chemotherapy.
Read Article
Ponatinib Approved for CML and Ph+ ALL
FDA Approvals, News & Updates
January 2013, Vol 4, No 1
The US Food and Drug Administration (FDA) approved ponatinib (Iclusig; ARIAD Pharmaceuticals) under its accelerated program for the treatment of patients with chronic- phase (CP), accelerated-phase (AP), or blast-phase (BP) chronic myeloid leukemia (CML) that is resistant to or intolerant to tyrosine kinase inhibitor (TKI) therapy or to Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) that is resistant to or intolerant to TKI therapy. The recommended dose is 45 mg, taken orally once daily, with no regard to food.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma